Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy
Journal
Clinical Cancer Research
Journal Volume
18
Journal Issue
14
Pages
3992-3997
Date Issued
2012
Author(s)
Abstract
Purpose: Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulinlike growth factor (IGF)-1 levels. We evaluated whether IGF-1 levels were associated with the outcomes of patients with advanced HCC treated with systemic antiangiogenic therapy. Experimental Design: The study was based on patients with advanced HCC who were enrolled in two clinical trials evaluating first-line combination antiangiogenic therapy. Serum samples were collected before treatment and four to six weeks after the start of treatment. The levels of IGF-1, IGF-2, and IGF-binding protein-3 (IGFBP3) were analyzed for their associations with treatment outcomes. Results: A total of 83 patients were included in the study. Patients who had high (?the median level) baseline IGF-1 levels had significantly higher disease control rate (DCR) than patients who had low (
SDGs
Other Subjects
bevacizumab; capecitabine; somatomedin B; somatomedin binding protein 3; somatomedin C; sorafenib; UFT; adult; advanced cancer; aged; antiangiogenic therapy; article; blood sampling; cancer control; cancer prognosis; female; human; liver cell carcinoma; major clinical study; male; metronomic drug administration; outcome assessment; overall survival; phase 2 clinical trial (topic); priority journal; progression free survival; protein analysis; protein blood level; survival time; treatment duration; treatment response; Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Tegafur; Treatment Outcome
Type
journal article